SAN CARLOS, Calif.--(BUSINESS WIRE)--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced today positive top-line ...
Cell Signaling Technology, Inc. (CST) has announced an agreement with Novartis under which a pilot study was performed using CST's PhosphoScan™ technology to identify phosphorylation sites and ...
The CST study was supposed to be conducted with BeiGene Ltd (NASDAQ: BGNE), which licensed the rights to VBR in China. The company will prioritize its portfolio of next-generation core inhibitors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback